Streetbeat News

SIGA

SIGA Technologies, Inc.

https://www.siga.com

Industry

Drug Manufacturers - Specialty & Generic

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security and infectious disease markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. has a strategic partnership with Cipla Therapeutics to deliver sustained innovation and access to antibacterial drugs primarily against biothreats. The company was incorporated in 1995 and is headquartered in New York, New York.

Open

6.18

Mkt cap

441M

Volume

416K

High

6.32

P/E Ratio

5.28

52-wk high

12.83

Low

5.94

Div yield

0.10

52-wk low

4.26

The article compares the performance of Siga Technologies Inc. (SIGA) and AnaptysBio, Inc. (ANAB) against their sector peers in the medical field for the current year.

Portfolio Pulse from

December 11, 2024 | 4:00 pm

The National Institutes of Health's NIAID announced interim results from the STOMP study, indicating that SIGA's antiviral treatment, tecovirimat, did not show efficacy in treating mild to moderate mpox. Consequently, the study's DSMB recommended halting patient enrollment in the study's randomized arms.

Portfolio Pulse from

December 10, 2024 | 9:15 pm

Siga Technologies (SIGA) is showing signs of potential recovery with a hammer chart pattern and positive earnings estimate revisions by analysts, suggesting a possible turnaround.

Portfolio Pulse from

December 05, 2024 | 4:00 pm

SIGA Technologies faces uncertainty due to reliance on TPOXX, mixed trial results, and upcoming contract renewal. Emergent BioSolutions shows promise with a diversified portfolio and new CEO strategy.

Portfolio Pulse from

December 02, 2024 | 11:00 pm

SIGA Technologies' stock has declined 37% since a previous 'speculative buy' recommendation due to a muted response to the mpox outbreak. The initial recommendation was based on the WHO's mpox emergency declaration and potential increased demand for SIGA's lead asset, tecovirimat. However, the outbreak has waned, and global authorities' response has been less aggressive, leading to lower-than-expected demand for tecovirimat.

Portfolio Pulse from

November 21, 2024 | 10:15 pm

The article discusses whether investors are undervaluing Siga Technologies (SIGA) by focusing on the Zacks Rank system, which emphasizes earnings estimates and revisions. It highlights the importance of value, growth, and momentum trends in identifying strong stock picks.

Portfolio Pulse from

November 21, 2024 | 4:00 pm

SIGA Technologies faces scrutiny after its Mpox therapy fails, leading to a significant drop in share prices and the termination of its Chief Medical Officer.

Portfolio Pulse from

November 08, 2024 | 2:30 pm

SIGA Technologies, Inc. held its Q3 2024 earnings call, discussing financial results and company performance.

Portfolio Pulse from

November 08, 2024 | 2:15 am

Levi & Korsinsky has initiated an investigation into SIGA Technologies, Inc. for potential violations of federal securities laws. This follows a video release where Dr. Varma discussed a media campaign to support TPOXX as a mpox treatment despite poor clinical trial results.

Portfolio Pulse from

November 07, 2024 | 12:45 pm

Levi & Korsinsky has initiated an investigation into SIGA Technologies, Inc. for potential violations of federal securities laws. This follows a video release showing efforts to manage media narratives around TPOXX's performance in a clinical trial.

Portfolio Pulse from

November 06, 2024 | 12:45 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.